Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFEGUARD study of SAB-142 in new-onset type 1 diabetes
2025-521560-36-00Phase 2Authorised
- Sponsor
- SAB BIO
- Start
- Apr 2026
- Modality
- Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing SAB-142 with Placebo (2 arms). Primary endpoints: Safety and tolerability and Pancreatic beta-cell function. Planned start Apr 2026; status: authorised.
02
Drugs
SAB-142
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2025-521560-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521560-36-00.